Table 4 |
||
|
Estimated dihydroartemisinin and total anti-malarial activity pharmacokinetic parameters. |
||
|
Parameter |
Estimate (SE) |
Inter-subject variation CV% |
|
|
||
|
DHA |
||
|
Ka (h -1) |
4.271 (2.091) |
|
|
CL/F1 (L kg-1 h-1) |
0.636 (0.075) |
|
|
Increase in CL/F due to the 3rd dose period |
0.760 (0.160) |
|
|
V/F (L kg-1) |
2.285 (0.317) |
47% |
|
Effect of Age on V/F |
0.063 (0.015) |
|
|
T 1/2 (h) |
||
|
1st dose |
2.5 [0.8–4.5]2 |
|
|
3rd dose |
1.1 [0.4–2.0]2 |
|
|
σ (ng/mL) |
340 |
|
|
Anti-malarial Activity |
||
|
Ka (h-1) |
4.744 (2.587) |
|
|
CL/F1 (L kg-1 h-1) |
0.616 (0.071) |
|
|
Increase in CL/F due to the 3rd dose period |
0.662 (0.150) |
|
|
V/F (L kg-1) |
2.134 (0.287) |
48% |
|
Effect of Age on V/F |
0.063 (0.013) |
|
|
T 1/2 (h) |
||
|
1st dose |
2.4 [0.5–5.7]2 |
|
|
3rd dose |
1.2 [0.2–2.7]2 |
|
|
σ (ng/mL) |
353 |
|
|
|
||
|
1population mean estimate of CL/F for the first dose period 290% range of predicted values; Ka – absorption rate constant; CL/F – total clearance; V/F – volume of distribution; F – fraction of drug absorbed; σ – residual additive error in DHA units |
||
|
Stepniewska et al. Malaria Journal 2009 8:200 doi:10.1186/1475-2875-8-200 |
||
